Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats

BJU International
Mizuaki SakuraKazunori Kihara

Abstract

To investigate the protective roles of type 4 phosphodiesterase (PDE4) inhibitor in cyclophosphamide (CYP)-induced haemorrhagic cystitis, as the PDE4 inhibitor has anti-inflammatory effects but its characterization is still unknown in urinary tract diseases. In female Sprague-Dawley rats, CYP was administered intraperitoneally and bladders were harvested 24 h after CYP injection. In another group, rolipram as a PDE4 inhibitor was administered before CYP treatment. The effects and mechanisms of CYP with/without rolipram pretreatment were evaluated by microscopic features, bladder wet weight, myeloperoxidase (MPO) activity, nitric oxide (NO)-metabolite production and expression levels of inflammation-related genes. CYP injection resulted in severe cystitis. Pretreatment with rolipram significantly reduced the increase in bladder wet weight and MPO activity, and ameliorated histological inflammatory changes caused by CYP. The levels of inflammation-related transcripts including inducible NO synthase (iNOS), interleukin-1beta and tumour necrosis factor-alpha, induced by CYP, were down-regulated significantly by pretreatment with rolipram. Also, rolipram reduced the NO-metabolite production and iNOS protein expression in the immunoh...Continue Reading

References

Sep 1, 1995·Clinical and Experimental Immunology·A R Moore, D A Willoughby
Mar 1, 1994·The European Respiratory Journal·P J Barnes, R A Pauwels
Feb 26, 1998·American Journal of Respiratory and Critical Care Medicine·T J Torphy
Dec 14, 1999·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·E Galea, D L Feinstein
Mar 14, 2000·Current Opinion in Cell Biology·S H Soderling, J A Beavo
Apr 4, 2001·Naunyn-Schmiedeberg's Archives of Pharmacology·A B AlfieriL X Cubeddu
Mar 2, 2002·Fertility and Sterility·Anne Van LangendoncktJacques Donnez
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·S-L Catherine Jin, Marco Conti
Dec 21, 2002·The Journal of Biological Chemistry·Marco ContiCatherine Jin
Jul 28, 2004·Trends in Pharmacological Sciences·Katharine H Banner, Michael A Trevethick
Dec 22, 2004·Journal of Gastroenterology and Hepatology·Tamotsu MatsuhashiSumio Watanabe
Jan 13, 2006·British Journal of Pharmacology·Victoria Boswell-SmithClive P Page

❮ Previous
Next ❯

Citations

Apr 24, 2014·The Journal of Sexual Medicine·Ana S F RibeiroMedardo Hernández
May 15, 2013·Nature Reviews. Urology·Mohammad S Rahnama'iGommert A van Koeveringe
Jun 4, 2011·European Journal of Clinical Pharmacology·Sonia RadiceEmilio Clementi
Mar 22, 2019·International Urology and Nephrology·Elif Nur BarutMine Kadioglu
Sep 3, 2021·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Minghan YongNuala Ann Helsby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here